Ulf Boemer

765 total citations
21 papers, 262 citations indexed

About

Ulf Boemer is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Ulf Boemer has authored 21 papers receiving a total of 262 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 5 papers in Oncology and 5 papers in Immunology. Recurrent topics in Ulf Boemer's work include PI3K/AKT/mTOR signaling in cancer (6 papers), Advanced Breast Cancer Therapies (3 papers) and Cancer Mechanisms and Therapy (3 papers). Ulf Boemer is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (6 papers), Advanced Breast Cancer Therapies (3 papers) and Cancer Mechanisms and Therapy (3 papers). Ulf Boemer collaborates with scholars based in Germany, United States and Egypt. Ulf Boemer's co-authors include Karl Ziegelbauer, Dominik Mumberg, Peter Ellinghaus, Stuart Ince, Michael Brands, Antje M. Wengner, Stefan Prechtl, Lorenzo Galluzzi, Dieter Zopf and Mohamed Jèmaà and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Ulf Boemer

20 papers receiving 257 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ulf Boemer Germany	8	182	77	61	32	32	21	262
Filipa M. Lopes United Kingdom	8	164 0.9×	36 0.5×	22 0.4×	29 0.9×	25 0.8×	24	258
Zhanzhan Feng China	14	273 1.5×	102 1.3×	50 0.8×	61 1.9×	35 1.1×	19	395
Heidrun Hirner Germany	10	272 1.5×	156 2.0×	54 0.9×	37 1.2×	44 1.4×	11	407
Dharmendra Dingar Canada	9	319 1.8×	69 0.9×	87 1.4×	31 1.0×	34 1.1×	13	393
Neil S. Dhawan United States	5	201 1.1×	57 0.7×	31 0.5×	24 0.8×	25 0.8×	9	250
Aurélie Dumont France	6	149 0.8×	80 1.0×	31 0.5×	11 0.3×	53 1.7×	9	229
Miryam Pastor Spain	8	255 1.4×	53 0.7×	97 1.6×	46 1.4×	38 1.2×	11	362
Widian F. Abi Saab United States	7	235 1.3×	54 0.7×	82 1.3×	8 0.3×	34 1.1×	7	324
Marisa Carbonaro United States	6	231 1.3×	101 1.3×	45 0.7×	25 0.8×	83 2.6×	11	387

Countries citing papers authored by Ulf Boemer

Since Specialization

Citations

This map shows the geographic impact of Ulf Boemer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ulf Boemer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ulf Boemer more than expected).

Fields of papers citing papers by Ulf Boemer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ulf Boemer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ulf Boemer. The network helps show where Ulf Boemer may publish in the future.

Co-authorship network of co-authors of Ulf Boemer

This figure shows the co-authorship network connecting the top 25 collaborators of Ulf Boemer. A scholar is included among the top collaborators of Ulf Boemer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ulf Boemer. Ulf Boemer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mowat, Jeffrey, Rafael Carretero, Gabriele Leder, et al.. (2024). Discovery of BAY-405: An Azaindole-Based MAP4K1 Inhibitor for the Enhancement of T-Cell Immunity against Cancer. Journal of Medicinal Chemistry. 67(19). 17429–17453. 7 indexed citations

Offringa, Rienk, Catherine Olesch, Frederik Cichon, et al.. (2024). 737 Optimal enhancement of anti-tumor T-cell immunity through the combined use of selective DGK zeta and DGK alpha inhibitors. Regular and Young Investigator Award Abstracts. A840–A840. 2 indexed citations

Offringa, Rienk, Catherine Olesch, Frederik Cichon, et al.. (2023). 926 BAY 2965501: a highly selective DGK zeta inhibitor for cancer immunotherapy. SHILAP Revista de lepidopterología. A1029–A1029. 1 indexed citations

Siegel, Franziska, Stephan Siegel, Gizem Karsli-Uzunbas, et al.. (2022). BAY 2927088: The first non-covalent, potent, and selective tyrosine kinase inhibitor targeting EGFR exon 20 insertions and C797S resistance mutations in NSCLC. European Journal of Cancer. 174. S9–S10. 6 indexed citations

Leder, Gabriele, Rafael Carretero, Jeffrey Mowat, et al.. (2021). Abstract 1722: Enhancement of anti-tumor T-cell immunity by means of an oral small molecule targeting the intracellular immune checkpoint MAP4K1. Cancer Research. 81(13_Supplement). 1722–1722. 1 indexed citations

Grünewald, Sylvia, Oliver Politz, Sebastian Bender, et al.. (2019). Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models. International Journal of Cancer. 145(5). 1346–1357. 72 indexed citations

Lange, Martin, Antje M. Wengner, Ulrich Bothe, et al.. (2018). Abstract 1887: Preclinical evaluation of a novel interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor in combination with PI3K inhibitor copanlisib or BTK inhibitors in ABC-DLBCL. Cancer Research. 78(13_Supplement). 1887–1887. 1 indexed citations

Politz, Oliver, Stuart Ince, Andrea Haegebarth, et al.. (2016). Abstract 379: Allosteric AKT1/2-inhibitor BAY 1125976 as potent inhibitor in luminal breast cancer resistant to antihormone therapy. Cancer Research. 76(14_Supplement). 379–379. 2 indexed citations

Siegel, Franziska, Antje M. Wengner, Claudia Lange, et al.. (2016). Abstract 341: Preclinical mode of action and anti-tumor efficacy of the selective MKNK1 inhibitor BAY 1143269 in NSCLC models. Cancer Research. 76(14_Supplement). 341–341. 1 indexed citations

10.

Scholz, Arne, Gerhard Siemeister, Philip Lienau, et al.. (2015). Abstract DDT02-02: BAY 1143572: A first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, inhibits MYC and shows convincing anti-tumor activity in multiple xenograft models by the induction of apoptosis. Cancer Research. 75(15_Supplement). DDT02–2. 8 indexed citations

11.

Siegel, Franziska, Claudia Schneider, Ulf Boemer, et al.. (2015). Abstract 2604: Preclinical anti-tumor efficacy and mode of action of a novel, orally available, selective MKNK1 inhibitor [BAY 1143269]. Cancer Research. 75(15_Supplement). 2604–2604. 3 indexed citations

12.

Héroult, Mélanie, Peter Ellinghaus, Dirk Brohm, et al.. (2014). Abstract 1739: Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial. Cancer Research. 74(19_Supplement). 1739–1739. 9 indexed citations

13.

Schueler, Julia, Michael Haerter, Ulf Boemer, et al.. (2014). Abstract 1026: Novel Tie2 inhibitor with in vivo efficacy in disseminated hematological tumor models in mice. Cancer Research. 74(19_Supplement). 1026–1026. 1 indexed citations

14.

Politz, Oliver, Arne Scholz, Andrea Haegebarth, et al.. (2014). Abstract 3685: BAY 1125976, is a selective allosteric AKT1/2 inhibitor with high efficacy in AKT1-mutated cancers. Cancer Research. 74(19_Supplement). 3685–3685. 1 indexed citations

15.

Jèmaà, Mohamed, Lorenzo Galluzzi, Oliver Kepp, et al.. (2013). Characterization of novel MPS1 inhibitors with preclinical anticancer activity. Cell Death and Differentiation. 20(11). 1532–1545. 83 indexed citations

16.

Politz, Oliver, Stuart Ince, William J. Scott, et al.. (2013). Abstract 2050: BAY 1125976, a highly selective and potent allosteric AKT1/2 inhibitor, for the treatment of cancers with aberrations in the PI3K-AKT-mTOR pathway.. Cancer Research. 73(8_Supplement). 2050–2050. 2 indexed citations

17.

Brockschnieder, Damian, Heribert Schmitt‐Willich, Tobias Heinrich, et al.. (2012). Preclinical Characterization of a Novel Class of¹⁸F-Labeled PET Tracers for Amyloid-β. Journal of Nuclear Medicine. 53(11). 1794–1801. 19 indexed citations

18.

Liu, Ningshu, William J. Scott, Andrea Haegebarth, et al.. (2012). Abstract 2799: BAY 1082439, a highly selective and balanced PI3Kα/β inhibitor demonstrated potent activity in tumors with activated PI3Kα and loss-of-function of PTEN. Cancer Research. 72(8_Supplement). 2799–2799.

19.

Fanghänel, Jörg, Martina Schäfer, Volker Badock, et al.. (2011). A crystallographic fragment screen identifies cinnamic acid derivatives as starting points for potent Pim-1 inhibitors. Acta Crystallographica Section D Biological Crystallography. 67(3). 156–166. 16 indexed citations

20.

Bergsdorf, Christian, et al.. (2008). A One-Day, Dispense-Only IP-One HTRF Assay for High-Throughput Screening of G _{α q} Protein-Coupled Receptors: Towards Cells as Reagents. Assay and Drug Development Technologies. 6(1). 39–53. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact